Latigo Biotherapeutics (LTGO) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MannKind is the larger company by market cap ($1.10 billion vs $980.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTGO | MNKD |
|---|---|---|
| Share price | $14.79 | $3.42 |
| Market cap | $980.57M | $1.10B |
| 1-day change | -4.70% | -0.87% |
| YTD return | — | -39.68% |
| 1-year return | — | -37.13% |
| 5-year return | — | -32.81% |
| Forward P/E | — | 26.82 |
| EPS (TTM) | $-2.41 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.93 | $6.51 |
| 52-week low | $14.60 | $2.23 |
| Distance from 52-week high | -42.96% | -47.47% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +253.28% | +129.24% |
| Average volume | 391.26K | 4.50M |
| Shares outstanding | 66.30M | 321.54M |
| Employees | 66 | 591 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Latigo Biotherapeutics in Health Care and MannKind in Healthcare.
About Latigo Biotherapeutics
LTGO stock →Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
LTGO vs MNKD FAQ
Which is bigger, Latigo Biotherapeutics or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.10B compared with $980.57M for Latigo Biotherapeutics (LTGO).
Are Latigo Biotherapeutics and MannKind in the same industry?
No. Latigo Biotherapeutics is in the Health Care sector, while MannKind is in Healthcare.